<DOC>
	<DOCNO>NCT00744692</DOCNO>
	<brief_summary>The primary objective determine feasibility attain acceptable rate donor cell engraftment ( &gt; 25 % donor chimerism 180 day ) follow reduce intensity conditioning ( RIC ) regimens pediatric patient &lt; 21 year receive cord blood transplantation non-malignant disorder .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Umbilical Cord Blood Transplant Pediatric Patients With Non-Malignant Disorders</brief_title>
	<detailed_description>Myeloablative dos chemotherapy and/or radiation therapy employ primary purpose eradicate malignant cell . Additionally , regimens exert vary degree immunosuppression/immunoablation aid reduce likelihood rejection host hematopoietic cell . However , myeloablative /immunoablative regimen also associate significant regimen relate toxicity ( RRT ) regimen relate mortality ( RRM ) may cause death 20 % patient significantly high rate severe organ dysfunction failure . While RRT occur typically first 100 day [ e.g . VOD ( veno occlusive disease ) , pulmonary intracranial hemorrhage , multiorgan failure ( MOF ) ] , significant long term toxicity TBI and/or chemotherapy include growth impairment , gonadal dysfunction/failure , hypothyroidism , cataract , neurocognitive impairment , second malignancy . The primary objective determine feasibility attain acceptable rate donor cell engraftment ( &gt; 25 % donor chimerism 180 day ) follow reduce intensity conditioning ( RIC ) regimens pediatric patient &lt; 21 year receive cord blood transplantation non-malignant disorder . The secondary objective : - To describe pace neutrophil platelet recovery - To evaluate pace immune reconstitution . - To determine treatment related mortality , overall survival disease free survival day 100 180 post-transplant - To describe incidence acute Graft Versus Host Disease ( GVHD ) ( II - IV ) chronic extensive GVHD - To describe incidence grade 3-4 organ toxicity - To evaluate long-term complication , sterility , endocrinopathy , growth failure - To evaluate incidence late graft failures 2 year post-transplant</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<criteria>021 year age diagnosis immunodeficiency , congenital marrow failure syndrome , inborn error metabolism , hereditary anemia Appropriately match related unrelated umbilical cord blood unit cell dose ≥ 3 x 10e7cells/kg Performance score ( lansky karnofsky ) great equal 70 Adequate organ function ( Creatinine ≤ 2.0 mg/dl creatinine clearance ≥ 50 ml/min/1.73 m2 ; Hepatic transaminase ( ALT/AST ) ≤ 4 x normal ; Shortening fraction &gt; 26 % ejection fraction &gt; 40 % &gt; 80 % normal value age ; Pulmonary function test demonstrate CVC FEV1/FVC &gt; 60 % predicted age . ) Informed consent Not pregnant breast feeding Minimum life expectancy least 6 month HIV negative No uncontrolled infection time cytoreduction Disease specific inclusion criterion Patients hemoglobinopathy &gt; 3 year age UCB unit total nucleated cell count &lt; 3 x 10e7/kg &gt; 2 antigen mismatch Available HLAmatched relate live donor able donate without previous UCB donation Allogeneic hematopoietic stem cell transplant within previous 6 month Any active malignancy , MDS , history malignancy Severe acquire aplastic anemia DLCO &lt; 60 % normal value age ; requirement supplemental oxygen Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) Pregnancy nurse mother HIV/HTLV seropositive , Hep B surface antigen positive , HCV RNA positive PCR Any condition precludes serial followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Immunodeficiencies</keyword>
	<keyword>Congenital Marrow Failures</keyword>
	<keyword>Hemoglobinopathies</keyword>
	<keyword>Inborn Errors Metabolism</keyword>
	<keyword>SCIDS</keyword>
	<keyword>Wiskott Aldrich</keyword>
	<keyword>FEL</keyword>
	<keyword>HLH</keyword>
	<keyword>IPEX</keyword>
	<keyword>LAD</keyword>
	<keyword>Sickle Cell</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Omenn 's Syndrome</keyword>
	<keyword>Hurler 's Syndrome</keyword>
	<keyword>MLD</keyword>
	<keyword>ALD</keyword>
	<keyword>Sanfilippo</keyword>
	<keyword>Krabbe</keyword>
	<keyword>Hunter 's syndrome</keyword>
	<keyword>TaySachs</keyword>
	<keyword>Diamond Blackfan Anemia</keyword>
	<keyword>transplant</keyword>
	<keyword>MPS</keyword>
	<keyword>Gaucher</keyword>
</DOC>